PARIS Feb 13 French drugmaker Sanofi
said on Wednesday it would invest 44 million euros ($59 million)
on its site in Waterford, Ireland, to boost production of its
top-selling insulin, Lantus.
The company, which has been reshuffling research and
production sites in the United States and Europe after the
patent loss of several key medicines, aims to start making
Lantus at the site in 2016, Sanofi said in a statement.
Lantus is expected to continue its double-digit sales growth
after the U.S. Food and Drug Administration this week refused to
approve Novo Nordisk's rival insulin Tresiba until
the Danish company conducts extra tests for potential heart